MedImmune, Inc. To Announce 2006 First Quarter Financial Results On April 20, 2006
GAITHERSBURG, Md., March 30 /PRNewswire-FirstCall/ -- MedImmune, Inc.'s 2006 first-quarter financial results are expected to be released on Thursday, April 20, 2006 before the opening of the U.S. financial markets. The company is also planning to host a conference call and live audio webcast at 8:00 a.m. eastern time following the announcement. During the conference call, MedImmune's management will discuss the financial results and other business.
The press release and the live webcast can be accessed by going to the Investor Relations section of the MedImmune website at http://www.medimmune.com. An archived version of the call will be available at the same address for one week after the live webcast.
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,000 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com.
This announcement contains forward-looking statements including that the company expects to disseminate financial information for the first quarter of 2006. Such statements reflect management's current views and are based on certain assumptions, including but not limited to, completion of the company's quarter-end closing procedures and completion of certain quarter-end review procedures. There can be no assurance that such procedures will be completed in the timeframe allotted or for those reasons or any others, that the company will not choose to disseminate such financial information on a different date and/or time.MedImmune, Inc.
CONTACT: Investors: Peter Vozzo, +1-301-398-4358, or Media: Jamie Lacey,+1-301-398-4035, both of MedImmune, Inc.
Web site: http://www.medimmune.com/